Meridia is a drug owned by Abbott Laboratories Pharmaceutical Products Div. It is protected by 2 US drug patents filed in 2013 out of which all have expired. Based on its patents and exclusivities, its generic launch date is estimated to be Jan 25, 2013. Details of Meridia's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
|
US5436272 (Pediatric) | Treatment of obesity |
Jan, 2013
(11 years ago) |
Expired
|
| US5436272 | Treatment of obesity |
Jul, 2012
(12 years ago) |
Expired
|
US patents provide insights into the exclusivity only within the United States, but Meridia is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Meridia's family patents as well as insights into ongoing legal events on those patents.
Meridia's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Meridia's generic launch date based on the expiry of its last outstanding patent is estimated to be Jan 25, 2013 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Meridia Generics:
There are no approved generic versions for Meridia as of now.
How can I launch a generic of Meridia before its drug patent expiration? :
You can seek FDA approval to launch a generic drug before the expiration of Meridia's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the Meridia's sponsor is invalid, unenforceable, or will not be infringed by your generic product.
Given below are the details of the already filed Para IV certificates on Meridia -
| Strength | Submission Date | ANDA(s) Filed | First applicant approval | Last patent expiry | 180 day status |
|---|---|---|---|---|---|
| 10 mg and 15 mg | 14 Aug, 2009 | 1 | 25 Jul, 2012 | Extinguished |
About Meridia
Meridia is a drug owned by Abbott Laboratories Pharmaceutical Products Div. It is used for weight loss in individuals with obesity. Meridia uses Sibutramine Hydrochloride as an active ingredient. Meridia was launched by Abbott in 1997.
Approval Date:
Meridia was approved by FDA for market use on 22 November, 1997.
Active Ingredient:
Meridia uses Sibutramine Hydrochloride as the active ingredient. Check out other Drugs and Companies using Sibutramine Hydrochloride ingredient
Treatment:
Meridia is used for weight loss in individuals with obesity.
Dosage:
Meridia is available in capsule form for oral use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 10MG | CAPSULE | Discontinued | ORAL |
| 15MG | CAPSULE | Discontinued | ORAL |
| 5MG | CAPSULE | Discontinued | ORAL |